Filing Flows › Globe Life (GL) › Guidance & outlook
Globe Life (GL) guidance and outlook
Globe Life (GL) updated its guidance on Oct 21, 2026: EPS $15.35–$15.65 for FY2026. Globe Life's 10-Q filed Nov 4, 2026 makes 13 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | FY2026 | $15.35–$15.65 | new |
From the earnings release filed Oct 21, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Excluding the impact of assumption changes, the Company's results for actual variances from expected experience for both life and health produced a $75.1 million net remeasurement gain and a $53.6 million net remeasurement gain for the nine months ended September 30, 2026 and 2025, respectively.
- Recent investments in new sales technologies, combined with growth in agency middle management, are expected to drive continued sales momentum.
- While increasing interest rates have resulted in a net unrealized loss from our available-for-sale debt securities included in accumulated other comprehensive income (loss) as of September 30, 2026, we are not concerned because we do not generally intend to sell, nor is it likely that we will be required to sell, the fixed maturities prior to their anticipated recovery.
- We believe this strategy is appropriate since our expected future cash flows are generally stable and predictable and the likelihood that we will need to sell invested assets to raise cash is low.
- For the remainder of 2026, the Company will continue to execute on its existing strategy by seeking to invest in assets that satisfy our quality and other objectives, while striving to maximize the risk-adjusted, capital-adjusted return.
- Since implementing our share repurchase program in 1986, we have used $11.6 billion to repurchase Globe Life Inc. common shares, after determining that the repurchases provide a greater risk-adjusted after-tax return than other alternatives and we expect to continue this program into the future.
- For the twelve months ended December 31, 2026, we project approximately $95 million in shareholder dividends, compared to the $86 million paid in 2025.
- This liquidity is available to the Company in the event additional funds are needed to support the targeted capital levels within our insurance subsidiaries.
- We target a consolidated Company Action Level RBC ratio of 300% to 320% for our U.S. insurance subsidiaries.
- We plan to use excess cash available at the Parent Company as efficiently as possible in the future.
- We will determine the best use of excess cash after ensuring that targeted capital levels are maintained in our insurance subsidiaries.
- If market conditions are favorable, we currently expect that share repurchases will continue to be a primary use of those funds.
Globe Life's latest quarter
Globe Life, Q3 2026: revenue $1.6B (+6% year over year), operating margin 27.6%, net earnings $361M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
Questions
Did Globe Life raise or lower its guidance?
Globe Life (GL) updated its guidance on Oct 21, 2026: EPS $15.35–$15.65 for FY2026.
What does Globe Life expect?
Excluding the impact of assumption changes, the Company's results for actual variances from expected experience for both life and health produced a $75.1 million net remeasurement gain and a $53.6 million net remeasurement gain for the nine months ended September 30, 2026 and 2025, respectively. Recent investments in new sales technologies, combined with growth in agency middle management, are expected to drive continued sales momentum. While increasing interest rates have resulted in a net unrealized loss from our available-for-sale debt securities included in accumulated other comprehensive
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.